SequelSEC

Acrivon Therapeutics, Inc. ACRV

Pharmaceutical Preparations · CIK 0001781174 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$84.11M
Fiscal year ended 2025-12-31
Free cash flow
-$65.33M
Fiscal year ended 2025-12-31

Acrivon Therapeutics, Inc. (ACRV) reported net income of -$77.90M for the fiscal year ended 2025-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from Acrivon Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Acrivon Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$84.11M-$89.20M-$67.10M-$32.66M-$16.18M
Net income-$77.90M-$80.56M-$60.39M-$31.17M-$16.24M
Research & development$59.99M$63.99M$46.02M$23.95MUnavailable
Weighted-average diluted sharesshares 38.51Mshares 33.79Mshares 22.08Mshares 4.12Mshares 1.74M
Pretax income-$77.82M-$80.44MUnavailableUnavailableUnavailable
Income tax expense$0UnavailableUnavailableUnavailableUnavailable
Diluted EPS$-2.02$-2.38$-2.74$-7.56$-9.32
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$24.12M$25.21M$21.08M$8.71MUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Acrivon Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
Cash & equivalents$41.50M$39.82M$36.02M$29.52M$99.60M
Total assets$129.72M$196.59M$138.26M$181.23M$106.59M
Current assets$120.44M$181.63M$129.69M$132.10M$100.41M
Total liabilities$17.20M$19.80M$17.07M$10.75M$7.88M
Current liabilities$15.66M$17.21M$13.30M$6.52M$2.91M
Total equity incl. NCI$112.52M$176.79M$121.20M$170.48M-$23.81M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$122.52M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.28M$758.00K$5.05M$904.00K$964.00K

Cash flow

Acrivon Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
Operating cash flow-$63.66M-$65.67M-$42.64M-$30.12M-$13.98M
Capital expenditures$1.67M$2.77M$1.29M$2.17M$238.00K
Investing cash flow$66.10M-$51.77M$50.72M-$141.68M-$238.00K
Financing cash flow-$749.00K$121.03M-$1.55M$101.71M$112.22M
Net change in cash$1.69M$3.59M$6.52M-$70.08M$98.00M
Stock-based compensation$14.72M$14.29M$11.62M$2.18M$497.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Acrivon Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
Free cash flow-$65.33M-$68.44M-$43.93M-$32.28M-$14.22M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio7.69x10.55x9.75x20.27x34.46x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ACRV in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACTU

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.